Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (1168)	1/2/2002 7:54:36 PM
From: SemiBull	Read Replies (1) \| Respond to of 1298

Abgenix to test its lead drug on cancer patients NEW YORK, Jan 2 (Reuters) - Abgenix Inc. (NasdaqNM:ABGX - news) said on Wednesday it plans to test its experimental anti-inflammatory drug in patients with cancer, potentially adding a new market for its leading drug candidate. The Fremont, California-based biotechnology company said it plans to test the drug in humans with metastatic melanoma, a serious form of skin cancer. Abgenix aims later to test the drug against other cancers including head and neck cancer, breast cancer, non-small cell lung cancer, ovarian cancer and brain cancer. Cancer is the fourth disease Abgenix hopes to attack with its drug, known as ABX-IL8. It is also testing it in patients with pulmonary disease, psoriasis - a skin disorder - and rheumatoid arthritis.